RxDoctor Payments DataLook up a doctor →

Jacqueline Erbse, APRN

Family · Bowling Green, KYNPI 1790169142

Payments from drug & device makers

$13,853in general payments, 2019–2025

Across 753 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$997
  • Takeda Pharmaceuticals U.S.A., Inc.$979
  • Janssen Scientific Affairs, LLC$635
  • Gilead$634
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$13,837100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,853 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$64,208
Medicare patients
223
Services billed
6,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase14$195,963
CreonLipase/Protease/Amylase24$50,162
LinzessLinaclotide63$49,179
TrulancePlecanatide64$41,630
MotegrityPrucalopride Succinate33$20,052
Mesalamine16$8,456
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates55$3,779
Sucralfate63$3,591
Pantoprazole Sodium330$3,331
Dexlansoprazole DrDexlansoprazole16$2,632
Lubiprostone17$2,242
Omeprazole172$1,927
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl77$1,215
Ondansetron Hcl12$929
Famotidine56$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$430$195,96314 claims
AbbVieCreon, Linzess$3,504$99,34087 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$2,346$41,63064 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$979$20,05233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →